Tyme Technologies

TYME Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s immune system.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices.

Tyme Technologies Offers Incredible Risk-Reward

Tyme Technologies, Inc. (TYME) CEO Richie Cunningham on Q2 2021 Results - Earnings Call Transcript

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its second fiscal quarter ended September 30, 2021. Second Fiscal Quarter 2022 Business and Recent Highlights: Commenced enrollment and dosed first patient in OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study examining SM-88 with methoxsa

TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business Officer, will present at the Jefferies London Healthcare Conference as follows: Date:     Wednesday, November 17, 2021       Time:     1:40 PM Greenwich Mean Time / 8:40 AM Eastern Standard Time       Webcast:

TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its second quarter 2022 financial results on Monday, November 8, 2021 at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Monday, November 8, 2021 Time: 8:

TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (“TYME” or the “Company”) (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the first patient has been dosed in the Phase II OASIS trial in patients with metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative (“HR+/HER2-“) breast cancer who previously received a CDK4/6 inhibitor regimen being conducted by Georgetown University (N

TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will present virtually at two upcoming healthcare conferences as follows:   H.C. Wainwright 23rd Annual Global Investment Conference Date: Monday, September 13, 2021 Time: On demand beginning at 7:00a

TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences

Tyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have addressed my downside concerns.

Tyme Technologies: The Market Missed The Bullish Memo

Tyme Technologies, Inc. (TYME) CEO Richie Cunningham on Q1 Fiscal Year 2022 Results - Earnings Call Transcript

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fiscal first quarter ended June 30, 2021. Fiscal First Quarter 2022 Business and Recent Highlights: Completed strategic review and identified clinical priorities with a focus on metastatic hormone receptor positive, human epidermal growth factor receptor 2 ne

TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its first quarter 2022 financial results on Tuesday, August 10, 2021 at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Tuesday, August 10, 2021 Time: 8:3

TYME Technologies, Inc. to Host Conference Call and Webcast on Tuesday, August 10th at 8:30 AM ET

Shares of Tyme Technologies, Inc. (NASDAQ: TYME) may have just crashed into a wall of sellers. This means the rally may be over.

Tyme Technologies Stock Rallies: A Technical Analysis

TYME stock is making big moves today after it received patent approval for its cancer treatment. Now, it will move into deeper development.

TYME Stock: The Cancer Treatment News That's Boosting Tyme Today

The stock price of Tyme Technologies Inc (NASDAQ: TYME) increased by over 64% pre-market. This is why it happened.

TYME Stock Increases Over 64% Pre-Market: Why It Happened

BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company's metabolomic technology platform. The patent, U.S. Patent No. 11,058,638, involves a targeted delivery of therapeutics to cancer cells. Tyme has developed a technology by which th

Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer

Axcella Health Inc

iBio

Looking for biotech penny stocks to watch before Monday? Check these 3 out The post Best Biotech Penny Stocks to Buy?

Best Biotech Penny Stocks to Buy? 3 to Watch Before Monday

Tyme Technologies Inc (NASDAQ: TYME) announced a breast cancer trial with Georgetown University named OASIS. Enrollment is expected to start in Q3 of 2021.

Tyme Stock Is Trading Higher On Pipeline Update After Strategic Review, Q4 Earnings

Tyme Technologies, Inc. (TYME) CEO Richie Cunningham on Q1 2021 Results - Earnings Call Transcript

BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (Nasdaq:TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today reported its conclusions from its recently conducted comprehensive strategic review and its fourth quarter and fiscal year 2021 financial results. “Following my appointment as CEO of TYME, I assembled a group of independent key opinion leaders and industry experts alongside our internal team and launche

Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results

Corbus Pharmaceuticals Holdings

Second Sight Medical Products

Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks That Are Popular on Reddit Right Now

Tyme Technologies continues to be a disappointing investment. Despite the discouraging price action, I am looking to accumulate shares in anticipation of the company's platform produces a game-changing therapy. I discuss the company's platform technology and why I am so bullish about Tyme's pipeline and long-term prospects.

Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount

Advaxis

Sesen Bio Inc.

T2 Biosystems

Biotech penny stocks are pushing up; here's 4 for your watchlist The post Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List

Abeona Therapeutics

CarLotz

Oriental Culture Holding

These penny stocks are pushing up, should you add them to your watchlist? The post Best Penny Stocks in 2021 So Far?

Best Penny Stocks in 2021 So Far? Here's 4 You Should Check Out

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTstm), today announced that it will host a conference call and live video webcast on Thursday, June 10, 2021 at 5:00 PM ET. The Company will report its fiscal year 2021 financial results and provide a business update that same day. As part of the event, the TYME executive management team will provide an updated bu

TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET

New Gold

Looking for top penny stocks to buy under $2? Check these 3 out for some watchlist inspiration The post 3 Penny Stocks To Watch Under $2 Making Big Moves Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Tyme Technologies Stock (TYME)